SG10201500028RA - Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same - Google Patents

Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same

Info

Publication number: SG10201500028RA
Authority: SG; Singapore
Prior art keywords: phenyl; decan; diaza; spiro; trifluoromethyl
Prior art date: 2006-04-05

Application number

SG10201500028RA

Inventor

Zhihui Qiu

Larisa Reyderman

Original Assignee

Opko Health Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-05

Filing date

2007-04-04

Publication date

2015-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38441502&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201500028R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-04-04 Application filed by Opko Health Inc filed Critical Opko Health Inc

2015-02-27 Publication of SG10201500028RA publication Critical patent/SG10201500028RA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG10201500028RA 2006-04-05 2007-04-04 Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same SG10201500028RA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US78951406P	2006-04-05	2006-04-05

Publications (1)

Publication Number	Publication Date
SG10201500028RA true SG10201500028RA (en)	2015-02-27

Family

ID=38441502

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201500028RA SG10201500028RA (en)	2006-04-05	2007-04-04	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same

Country Status (20)

Country	Link
US (4)	US7563801B2 (en)
EP (2)	EP2997964A1 (en)
JP (4)	JP5155998B2 (en)
KR (1)	KR20080108319A (en)
CN (2)	CN101460151B (en)
AR (1)	AR060303A1 (en)
AU (1)	AU2007233389C1 (en)
BR (1)	BRPI0710577A2 (en)
CA (2)	CA2861281A1 (en)
CL (1)	CL2007000945A1 (en)
ES (1)	ES2553805T3 (en)
HK (1)	HK1133387A1 (en)
MX (1)	MX2008012936A (en)
NO (1)	NO342810B1 (en)
NZ (1)	NZ571693A (en)
PE (2)	PE20080054A1 (en)
SG (1)	SG10201500028RA (en)
TW (1)	TWI332836B (en)
WO (1)	WO2007114921A2 (en)
ZA (1)	ZA200808465B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030762A1 (en)	2001-12-18	2003-09-05	Schering Corp	HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
KR20080108319A (en) *	2006-04-05	2008-12-12	쉐링 코포레이션	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one and treatment methods using the same
CA2648604C (en) *	2006-04-05	2016-05-24	Schering Corporation	Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
AR066191A1 (en)	2007-03-22	2009-08-05	Schering Corp	PROCESS AND INTERMEDIARIES FOR THE SYNTHESIS OF COMPOUNDS 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) PHENYL) - ETOXI) - METAL] - 8 PHENYL - 1,7- DIAZA - ESPIRO (4, 5) DECAN - 2 ONA
AR065802A1 (en) *	2007-03-22	2009-07-01	Schering Corp	FORMULATIONS OF TABLETS CONTAINING SALTS OF 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) FENIL) -ETOXI) - METHYL) -8- PHENYL -1, 7- DIAZA- SPIRO [4,5] DECAN - 2- ONA AND TABLETS PREPARED FROM THESE
CN104496988B (en)	2008-09-05	2017-04-12	欧科生医股份有限公司	Process And Intermediates For The Synthesis Of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one Compounds
WO2010077669A2 (en) *	2008-12-08	2010-07-08	Teva Pharmaceutical Industries Ltd.	Palonosetron formulation
EP3143996A1 (en)	2009-08-14	2017-03-22	OPKO Health, Inc.	Intravenous formulations of neurokinin 1-antagonists
EP3002005A1 (en) *	2014-09-30	2016-04-06	Molkerei Meggle Wasserburg GmbH & Co. Kg	Direct compression excipient based on lactose, cellulose and starch
CN104473887A (en) *	2014-11-12	2015-04-01	广东东阳光药业有限公司	Method for improving reproducibility of rivaroxaban tablet dissolution curve
CN106866669A (en) *	2017-04-19	2017-06-20	成都百特万合医药科技有限公司	A kind of method for synthesizing the smooth intermediate of roller pyrrole

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US431003A (en) *		1890-06-24		Store-service apparatus
GB1605190A (en) *	1968-08-23	1983-03-23	Phillips Petroleum Co	Armour plate
US4013613A (en) *	1971-10-01	1977-03-22	General Electric Company	Reinforced intercrystalline thermoplastic polyester compositions
US4079161A (en) *	1974-07-12	1978-03-14	Phillips Petroleum Company	Transparent oriented polyolefin laminated armor structure
FR2678971B1 (en) *	1991-07-08	1998-04-10	Andre Giraud	TRANSPARENT COMPOSITE STRUCTURAL ELEMENTS AND METHODS OF MAKING SAME.
US5830548A (en) *	1992-08-11	1998-11-03	E. Khashoggi Industries, Llc	Articles of manufacture and methods for manufacturing laminate structures including inorganically filled sheets
US5665450A (en) *	1992-08-21	1997-09-09	The Curators Of The University Of Missouri	Optically transparent composite material and process for preparing same
EP0666856B1 (en)	1992-10-28	2000-01-05	MERCK SHARP & DOHME LTD.	4-arylmethyloxymethyl piperidines as tachykinin antagonists
EP0673367A1 (en)	1992-12-14	1995-09-27	MERCK SHARP & DOHME LTD.	4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
DE69504300T2 (en)	1994-01-13	1999-04-29	Merck Sharp & Dohme	GEM BIT-SUBSTITUTED AZACYCLIC TACHYKININ ANTAGONISTS
US5733659A (en) *	1995-02-27	1998-03-31	Mitsubishi Engineering-Plastics Corporation	Transparent rigid resin molded product and process for producing the same
NZ302926A (en) *	1995-02-28	1998-10-28	Hoechst Marion Roussel Inc	Composition for use as antihistamines comprising piperidinoalkanol derivatives and inert ingredients
WO1997007804A1 (en)	1995-08-28	1997-03-06	Schering Corporation	Combination therapy for advanced cancer comprising temozolomide and cisplatin
US5759658A (en) *	1996-04-26	1998-06-02	Tables International Corporation	Composite panels, articles incorporating same and method
US5939098A (en)	1996-09-19	1999-08-17	Schering Corporation	Cancer treatment with temozolomide
US6630231B2 (en) *	1999-02-05	2003-10-07	3M Innovative Properties Company	Composite articles reinforced with highly oriented microfibers
ES2251987T3 (en) *	1999-03-30	2006-05-16	Schering Corporation	IMPROVED CANCER TREATMENT WITH TEMOZOLOMIDE.
US6499984B1 (en) *	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation
DE10053151A1 (en) *	2000-10-26	2002-05-08	Bayer Ag	Composition containing thermoplastic materials
PE20030592A1 (en)	2001-11-13	2003-07-07	Schering Corp	NK1 ANTAGONIST
PE20030762A1 (en)	2001-12-18	2003-09-05	Schering Corp	HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
US6818306B2 (en) *	2002-09-27	2004-11-16	The Boeing Company	Optically clear structural laminate
JP4874107B2 (en) *	2003-10-03	2012-02-15	ファイザー・インク	Imidazopyridine substituted tropane derivatives having CCR5 receptor antagonistic activity for the treatment of HIV and inflammation
US6889938B1 (en) *	2003-10-21	2005-05-10	The Boeing Company	Structural cockpit window and method of making same
AR046769A1 (en) *	2003-12-22	2005-12-21	Schering Corp	PHARMACEUTICAL COMPOSITIONS
BRPI0512958A (en)	2004-07-01	2008-04-22	Schering Corp	nk1 antagonists
BRPI0517976A (en)	2004-11-09	2008-10-21	Schering Corp	treatment methods
KR20080108319A (en) *	2006-04-05	2008-12-12	쉐링 코포레이션	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one and treatment methods using the same
CA2648604C (en)	2006-04-05	2016-05-24	Schering Corporation	Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
AR065802A1 (en)	2007-03-22	2009-07-01	Schering Corp	FORMULATIONS OF TABLETS CONTAINING SALTS OF 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) FENIL) -ETOXI) - METHYL) -8- PHENYL -1, 7- DIAZA- SPIRO [4,5] DECAN - 2- ONA AND TABLETS PREPARED FROM THESE
AR066191A1 (en)	2007-03-22	2009-08-05	Schering Corp	PROCESS AND INTERMEDIARIES FOR THE SYNTHESIS OF COMPOUNDS 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) PHENYL) - ETOXI) - METAL] - 8 PHENYL - 1,7- DIAZA - ESPIRO (4, 5) DECAN - 2 ONA
CN104496988B (en)	2008-09-05	2017-04-12	欧科生医股份有限公司	Process And Intermediates For The Synthesis Of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one Compounds
EP3143996A1 (en)	2009-08-14	2017-03-22	OPKO Health, Inc.	Intravenous formulations of neurokinin 1-antagonists

2007
- 2007-04-04 KR KR1020087026488A patent/KR20080108319A/en not_active Application Discontinuation
- 2007-04-04 JP JP2009504270A patent/JP5155998B2/en not_active Expired - Fee Related
- 2007-04-04 BR BRPI0710577-0A patent/BRPI0710577A2/en not_active Application Discontinuation
- 2007-04-04 CA CA2861281A patent/CA2861281A1/en not_active Abandoned
- 2007-04-04 CA CA2648640A patent/CA2648640C/en active Active
- 2007-04-04 PE PE2007000412A patent/PE20080054A1/en active IP Right Grant
- 2007-04-04 EP EP15176475.0A patent/EP2997964A1/en not_active Withdrawn
- 2007-04-04 PE PE2011001528A patent/PE20120254A1/en not_active Application Discontinuation
- 2007-04-04 WO PCT/US2007/008345 patent/WO2007114921A2/en active Application Filing
- 2007-04-04 SG SG10201500028RA patent/SG10201500028RA/en unknown
- 2007-04-04 ES ES07774641.0T patent/ES2553805T3/en active Active
- 2007-04-04 EP EP07774641.0A patent/EP2004148B1/en not_active Not-in-force
- 2007-04-04 US US11/732,663 patent/US7563801B2/en active Active
- 2007-04-04 AR ARP070101440A patent/AR060303A1/en unknown
- 2007-04-04 AU AU2007233389A patent/AU2007233389C1/en not_active Ceased
- 2007-04-04 CL CL2007000945A patent/CL2007000945A1/en unknown
- 2007-04-04 NZ NZ571693A patent/NZ571693A/en not_active IP Right Cessation
- 2007-04-04 TW TW096112177A patent/TWI332836B/en not_active IP Right Cessation
- 2007-04-04 MX MX2008012936A patent/MX2008012936A/en active IP Right Grant
- 2007-04-04 CN CN2007800206407A patent/CN101460151B/en not_active Expired - Fee Related
- 2007-04-04 CN CN201310495198.0A patent/CN103751186B/en not_active Expired - Fee Related
2008
- 2008-10-03 ZA ZA2008/08465A patent/ZA200808465B/en unknown
- 2008-11-04 NO NO20084660A patent/NO342810B1/en not_active IP Right Cessation
2009
- 2009-06-18 US US12/487,263 patent/US7981905B2/en active Active
- 2009-12-07 HK HK09111436.0A patent/HK1133387A1/xx not_active IP Right Cessation
2011
- 2011-07-18 US US13/184,926 patent/US8404702B2/en active Active
2012
- 2012-06-08 JP JP2012131109A patent/JP5415587B2/en not_active Expired - Fee Related
- 2012-12-07 JP JP2012268500A patent/JP5640065B2/en not_active Expired - Fee Related
2013
- 2013-03-19 US US13/847,242 patent/US9345692B2/en active Active
2014
- 2014-10-27 JP JP2014218278A patent/JP6035305B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2648640A1 (en)	2007-10-11
US7563801B2 (en)	2009-07-21
NO20084660L (en)	2008-11-04
US8404702B2 (en)	2013-03-26
CA2861281A1 (en)	2007-10-11
WO2007114921A3 (en)	2008-03-27
CN103751186B (en)	2016-08-24
JP6035305B2 (en)	2016-11-30
MX2008012936A (en)	2008-10-15
WO2007114921A2 (en)	2007-10-11
US9345692B2 (en)	2016-05-24
CA2648640C (en)	2016-02-16
JP5640065B2 (en)	2014-12-10
AU2007233389B2 (en)	2013-02-28
HK1133387A1 (en)	2010-03-26
JP2015071603A (en)	2015-04-16
JP2012167125A (en)	2012-09-06
ZA200808465B (en)	2011-03-30
EP2004148A2 (en)	2008-12-24
AU2007233389A1 (en)	2007-10-11
US20120015921A1 (en)	2012-01-19
PE20120254A1 (en)	2012-03-26
JP2013049720A (en)	2013-03-14
KR20080108319A (en)	2008-12-12
US20140088128A1 (en)	2014-03-27
JP5415587B2 (en)	2014-02-12
US20070275051A1 (en)	2007-11-29
NZ571693A (en)	2011-12-22
JP2009532473A (en)	2009-09-10
AU2007233389C1 (en)	2013-07-25
ES2553805T3 (en)	2015-12-11
CN101460151B (en)	2013-11-20
EP2004148B1 (en)	2015-07-15
BRPI0710577A2 (en)	2011-08-16
NO342810B1 (en)	2018-08-13
CN103751186A (en)	2014-04-30
TWI332836B (en)	2010-11-11
PE20080054A1 (en)	2008-02-25
CN101460151A (en)	2009-06-17
EP2997964A1 (en)	2016-03-23
CL2007000945A1 (en)	2008-01-25
TW200808312A (en)	2008-02-16
JP5155998B2 (en)	2013-03-06
US20100137348A1 (en)	2010-06-03
AR060303A1 (en)	2008-06-04
US7981905B2 (en)	2011-07-19

Publication	Publication Date	Title
SG10201500028RA (en)	2015-02-27	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
HUS1700037I1 (en)	2017-11-28	Hydrochloride salt of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
TWI350185B (en)	2011-10-11	Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one salts and tablets made therefrom
IL205220A0 (en)	2011-07-31	8 - [4 - (1 - AMINOCYCLOBUTYL)PHENYL]-9- PHENYL [1,2,4] TRIAZOLO [3,4-f]- 1,6 - NAPHTHYRIDINS AND THEIR USE FOR THE PREPARATION OF A MEDICAMENT FOR TREATING CANCER
HK1138589A1 (en)	2010-08-27	Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
ZA200807767B (en)	2009-08-26	Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
IL194770A0 (en)	2009-08-03	6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine and its use as a medicament
IL207757A (en)	2015-07-30	3-[4(hetroaryl-methyl-amino)-aryl-carbonyl-amino]-propionic acid derivatives and medicaments comprising the same
IL206395A (en)	2015-04-30	N-heterocyclyl-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and pharmaceutical compositions comprising them
SI2069342T1 (en)	2010-09-30	2-ARYL-6-PHENYLIMIDAZO?á1,2-A?åPYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
WO2008148074A3 (en)	2009-03-19	Inhibitors of mtor and methods of treatment using same
IL199397A (en)	2014-07-31	Heterocyclic compounds, pharmaceutical compositions comprising them and medical uses thereof
EP1984370A4 (en)	2010-03-31	Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
WO2008021492A3 (en)	2008-10-09	Containment systems and components for animal husbandry
HK1098700A1 (en)	2007-07-27	Use of drug combinations for treating insulin resistance
ZA200606606B (en)	2008-02-27	Substituted Azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
IL195528A (en)	2014-07-31	Pyridazine compound, methods for its preparation, pharmaceutical composition comprising the same, use thereof and intermediate
WO2007128973A3 (en)	2008-05-02	Interleukin 1-receptor antagonist composition to treat restenosis
SG10201501749WA (en)	2015-05-28	Methods for administering long-lasting hypoglycemic agents
AP2150A (en)	2010-09-04	Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication.
IL201252A0 (en)	2010-05-31	New nitrogenated heterocyclic compounds, their preparation and use as antibacterial drugs
EP2366691A4 (en)	2012-05-09	The nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof
SI2151439T1 (en)	2014-05-30	Nitrogenated aromatic 6-membered ring derivative, and pharmaceutical agent comprising the same
IL177456A0 (en)	2006-12-10	Substituted azetidine compounds, their preparation and use as medicaments
WO2008057196A3 (en)	2008-07-24	Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases